[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2021 World Virology and Bacteriology 90-County Market Assessment-100 Respiratory, STD, Enteric and Other Tests-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

January 2021 | 2365 pages | ID: 2E574A31F7D7EN
Venture Planning Group

US$ 38,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This unique 90-country survey from LeadingMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.

The report is available by section, and can be customized to specific information needs and budget.

The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.

Rationale

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.

The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world’s major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

Geographic Regions and Countries

Asia-Pacific

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam

Europe

Albania, Austria, Belarus, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia, Lithuania, Malta, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, Ukraine

Latin America

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Middle East

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

North America

Canada, Mexico, USA

Market Segmentation Analysis
  • Sales and market shares of major suppliers of infectious disease diagnostic products in major countries by test.
  • Test and sales forecasts for 100 infectious disease diagnostic assays by country, individual test and market segment:
  • Review of market dynamics, trends, structure, size, growth and major suppliers.
Current and Emerging Products
  • In-depth examination of major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
  • Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
Technology Review
  • Assessment of emerging diagnostic technologies and their potential applications for infectious disease testing.
  • Companies developing or marketing infectious disease diagnostic products by individual test.
Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

Opportunities and Strategies for Suppliers
  • Emerging opportunities for new instrumentation, reagent systems, IT and other products with significant market appeal during the next five years.
  • Design criteria for decentralized testing products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
Contains 2,365 pages and 991 tables
I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. WORLDWIDE OVERVIEW OF MAJOR TESTS, TECHNOLOGIES AND INSTRUMENTATION

A. Major Infectious Disease Tests
  1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
  2. Adenovirus
  3. Aeromonas
  4. Anthrax/Bacillus Anthracis
  5. Arboviruses
  6. Babesiosis
  7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
  8. Blastocystis Hominis
  9. Brucella
  10. Campylobacter
  11. Candida
  12. Carbapenemase
  13. Chagas Disease
  14. Chancroid
  15. Chlamydia
  16. Clostridium Difficile
  17. Coronaviruses
  18. Coxsackieviruses
  19. Creutzfeldt-Jakob’s Disease
  20. Cryptosporidium Parvum
  21. Cyclospora Cayetanensis
  22. Cytomegalovirus
  23. Ebola Virus
  24. E. Coli
  25. Echovirus
  26. Encephalitis
  27. Enteroviruses
  28. Epstein-Barr Virus
  30. Giardia Lamblia
  31. Gonorrhea
  32. Granuloma Inguinale
  33. Hantavirus
  34. Helicobacter Pylori
  35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
  36. Herpes Simplex Virus
  37. Human Herpes Virus-6 (HHV-6)
  38. Influenza Viruses
  39. Legionella
  40. Lyme Disease
  41. Lymphogranuloma Venereum (LGV)
  42. Malaria
  43. Measles (Rubeola)
  44. Meningitis
  45. Microsporidium
  46. Mononucleosis
  47. Mumps
  48. Mycoplasma
  49. Norovirus
  50. Papillomaviruses
  51. Parvovirus B19
  52. Pneumonia
  53. Polyomaviruses
  54. Pseudomonas Aeruginosa
  55. Rabies
  56. Respiratory Syncytial Virus (RSV)
  57. Rhinoviruses
  58. Rotavirus
  59. Rubella
  60. Salmonellosis
  61. Septicemia
  62. Shigellosis

VII. COUNTRY MARKET ANALYSES: INFECTIOUS DISEASE SCREENING TEST

Volume and Sales Forecasts for 90 Countries
Albania, Argentina, Australia, Austria, Bahrain, Bangladesh, Belarus, Belgium, Bolivia, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Haiti, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kuwait, Latvia, Lebanon, Lithuania, Malaysia, Malta, Mexico, Moldova, Myanmar, Netherlands, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, UK, Ukraine, United Arab Emirates, Uruguay, USA, Venezuela, Vietnam

VIII. COMPETITIVE ASSESSMENTS

Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
Ortho-Clinical Diagnostics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
Quidel
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
Wako Chemical


More Publications